Related Experiment Video
Updated: May 31, 2026
A11-positive β-amyloid Oligomer Preparation and Assessment Using Dot Blotting Analysis
Published on: May 22, 2018
The inhibition of the Aβ-ASC interaction site suppresses β-amyloid aggregation and cytotoxicity
Lan Zhao1, Xue Xia1, Siqi Wang1
1National Engineering Laboratory for AIDS Vaccine, School of Life Sciences, Jilin University, Changchun, China.
Background And Aims:
The deposition of β-amyloid (Aβ) in the cerebral cortex and hippocampus is a key pathological hallmark of Alzheimer's disease (AD). Previous studies have shown that ASC specks released by activated microglia can bind to Aβ and promote its aggregation, thereby accelerating AD progression. However, the specific mechanisms underlying this interaction remain poorly understood. This study aims to identify the interaction sites between ASC and Aβ, design a vaccine targeting these sites, and evaluate its immunogenicity and therapeutic efficacy.
Methods:
The interaction regions between ASC and Aβ were identified using pull-down and ELISA assays. Four types of nanoparticle carriers were purified using a prokaryotic expression system, and two peptides targeting the interaction sites were synthesized in vitro. These peptides were conjugated to the carriers via the SpyCatcher-SpyTag system. C57BL/6J mice were immunized with the constructed nanoparticles, and the immunogenicity of the vaccines was assessed by ELISA, while safety was evaluated by ELISpot. Serum antibodies were purified for further functional analysis.
Results:
Pull-down and ELISA results demonstrated that the C-terminal region of Aβ, particularly residues 29-42, and the pyrin domain (PYD) of ASC are key regions involved in binding. Eight nanoparticle vaccines carrying Aβ C-terminal epitopes were successfully prepared. Among them, the Ferritin-based Aβ vaccine induced a potent immune response targeting the Aβ-ASC interaction site without activating Aβ-specific T-cell responses. In vitro functional assays confirmed that the purified antibodies effectively disrupted Aβ-ASC binding, inhibited Aβ aggregation, and subsequently reduced its neurotoxicity.
Discussion:
Our findings indicate that the interaction site between ASC and Aβ is located within amino acids 29-42 of Aβ. Vaccines designed based on this site, Ferritin-Aβ29-35-3copy and Ferritin-Aβ36-42-3copy, effectively induced antibody production. The resulting antibodies suppressed Aβ aggregation and the neurotoxicity of Aβ oligomers. These data suggest that the Aβ-ASC interaction site may represent a potential target for AD therapy.
Insights
This study identified the binding site between beta-amyloid (Aβ) and ASC, developing a nanoparticle vaccine that targets this interaction. The vaccine successfully generated antibodies to reduce Aβ aggregation and neurotoxicity, offering a potential Alzheimer's disease therapy.
Area of Science:
- Neuroscience
- Immunology
- Biochemistry
Background:
- Alzheimer's disease (AD) is characterized by beta-amyloid (Aβ) deposition in the brain.
- ASC specks from microglia bind to Aβ, promoting aggregation and accelerating AD.
- The precise interaction mechanisms between ASC and Aβ are not fully understood.
Purpose of the Study:
- To identify the specific interaction sites between ASC and Aβ.
- To design and evaluate a novel nanoparticle vaccine targeting these interaction sites for Alzheimer's disease therapy.
- To assess the immunogenicity and therapeutic efficacy of the developed vaccine.
Main Methods:
- Identified ASC-Aβ interaction regions using pull-down and ELISA assays.
- Developed nanoparticle vaccines by conjugating synthesized peptides to carriers via the SpyCatcher-SpyTag system.
- Assessed vaccine immunogenicity, safety, and antibody functionality in C57BL/6J mice.
Main Results:
- The C-terminal region of Aβ (residues 29-42) and ASC's pyrin domain (PYD) are key binding sites.
- Ferritin-based Aβ vaccines induced potent immune responses targeting the Aβ-ASC interaction site without activating detrimental T-cell responses.
- Generated antibodies effectively disrupted Aβ-ASC binding, inhibited Aβ aggregation, and reduced neurotoxicity.
Conclusions:
- The Aβ C-terminal region (amino acids 29-42) is a critical interaction site with ASC.
- Targeting the Aβ-ASC interaction site with nanoparticle vaccines like Ferritin-Aβ29-35-3copy and Ferritin-Aβ36-42-3copy is a promising therapeutic strategy for Alzheimer's disease.
- The developed antibodies show potential for suppressing Aβ aggregation and mitigating Aβ oligomer neurotoxicity.
Related Concept Videos
03:03Amyloid Fibrils
Amyloid deposits were observed as early as 1639 in the liver and the spleen. In 1854, Rudolph Virchow performed iodine staining, normally used to...
01:19Allosteric Proteins-ATCase
Aspartate transcarbamoylase (ATCase) is a cytosolic enzyme that catalyzes the condensation of L-aspartate and carbamoyl phosphate to N-carbamoyl-L-aspartate. This reaction is the first step in pyrimidine biosynthesis. UTP and CTP, the end products of the pyrimidine synthesis pathway,...
01:18Indirect-Acting Cholinergic Agonists: Mechanism of Action
Reversible inhibitors like edrophonium bind to a specific part of the enzyme called the anionic catalytic site. They form noncovalent bonds, which means they are not strongly attached to the enzyme. This creates a temporary and less stable enzyme–inhibitor complex, leading to...
01:22Alzheimer's Disease: Treatment
01:30Ligand-Gated Ion Channel Receptor: Gating Mechanism